摘要
Objective: To explore the potential of dexrazoxane to suppress subclinical cardiotoxicity in MS patients receiving mitoxantrone. Methods: An open-label study was performed to evaluate possible subclinical cardiotoxicity in multiple sclerosis patients treated quarterly with mitoxantrone (48mg/m2 cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventriculography. Results: No patient experienced symptoms of heart failure. Patients receiving dexrazoxane, which is cardioprotective for anthracyclines, exhibited a significantly lesser decline in left ventricular ejection fraction (mean change, - 3.80% vs - 8.55% , p < 0.001). Interpretation: These results support a cardioprotective effect of dexrazoxane in mitoxantrone treated multiple sclerosis patients.
Objective： To explore the potential of dexrazoxane to suppress subclinical cardiotoxicity in MS patients receiving mitoxantrone. Methods： An open-label study was performed to evaluate possible subclinical cardiotoxicity in multiple sclerosis patients treated quarterly with mitoxantrone （48mg/m^2 cumulative）, with and without concomitant dexrazoxane, using blinded serial radionucleide ventriculography. Results： No patient experienced symptoms of heart failure. Patients receiving dexrazoxane, which is cardioprotective for anthracyclines, exhibited a significantly lesser decline in left ventricular ejection fraction （mean change, - 3.80% vs - 8.55%, p 〈 0. 001）. Interpretation： These results support a cardioprotective effect of dexrazoxane in mitoxantrone treated multiple sclerosis patients.
出处
《世界核心医学期刊文摘（神经病学分册）》
2006年第5期10-10,共1页
Digest of the World Core Medical Journals:Clinical Neurology
